A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.

CHM 2101 - Chimeric Therap

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

Jennifer Eads; Maria Pia Morelli; Daniel Olson; Jason Litten; Stephanie Astrow; Meredith Pelster

Dec 17, 2024